Trial · NCT00977171
Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome
NCT00977171, Phase 2, Terminated, Chelsea Therapeutics; results first posted 2014-06-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome. Trials, record NCT00977171. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00977171
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome
- NCT number
- NCT00977171
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 3 participants, actual
- Lead sponsor
- Chelsea Therapeutics
- Conditions
- Chronic Fatigue Syndrome, Orthostatic Hypotension, Neurally Mediated Hypotension, Neurogenic Orthostatic Hypotension
- Interventions
- Droxidopa
- First posted
- 2009-09-15
- Last updated
- 2014-06-09
- Results first posted
- 2014-06-09
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Patient Global Impression of Improvement | Baseline to end of 12 week treatment period | The CGI-I is a 7 point scale ranging from a score of 1 (very much improved) to 7 (very much worse), with no change in the middle, and assesses the improvement in relation to the baseline evaluation. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Patient Global Impression of Improvement | Baseline to end of 12 week treatment period | 3 patients enrolled in the study prior to it being stopped due to difficulty enrolling patients. | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Patient Global Impression of Improvement | Droxidopa | 3 | Standard Deviation 2.64 | units on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Droxidopa | 3 | |
| Overall Study | COMPLETED | Droxidopa | 3 | |
| Overall Study | NOT COMPLETED | Droxidopa | 0 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Localised infection | Infections and infestations | Droxidopa | 1 | 3 | 1 |
| other | Nausea | Gastrointestinal disorders | Droxidopa | 2 | 3 | 6 |
| other | Heart rate increased | Investigations | Droxidopa | 1 | 3 | 1 |
| other | Diarrhoea | Gastrointestinal disorders | Droxidopa | 1 | 3 | 1 |
| other | Fibromyalgia | Musculoskeletal and connective tissue disorders | Droxidopa | 1 | 3 | 1 |
| other | Abdominal pain upper | Gastrointestinal disorders | Droxidopa | 1 | 3 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Droxidopa | ||
| Total, other adverse events | Droxidopa | 3 | 3 |
| Total, serious adverse events | Droxidopa | 0 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00977171
GET https://conductscience.org/api/trials/v1/NCT00977171/registered